# A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

> **NCT06649110** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 232 (estimated)

## Conditions studied

- Healthy Volunteers, Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** LTP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06649110
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2028-11-29
- **Final completion:** 2028-12-31
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649110, "A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06649110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*